NCT03036163View on ClinicalTrials.gov

Phase 1 Study of PBTZ169

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

November 30, 2016

Conditions
Tuberculosis
Interventions
DRUG

PBTZ169 - 40 mg

40 mg of PBTZ169 (1 capsule) orally once in fasting state

DRUG

PBTZ169 - 80 mg

80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state

DRUG

PBTZ169 - 160 mg

160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state

DRUG

PBTZ169 - 320 mg

320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state

DRUG

PBTZ169 - 640 mg

640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state

DRUG

PBTZ169 - 320 mg (multiple administration)

320 mg of PBTZ169 (8 capsules 40 mg) orally once per day in fasting state for 14 days

DRUG

PBTZ169 - 640 mg (multiple administration)

640 mg of PBTZ169 (16 capsules 40 mg) orally once per day in fasting state for 14 days

All Listed Sponsors
collaborator

OCT LLC

INDUSTRY

lead

Nearmedic Plus LLC

INDUSTRY

NCT03036163 - Phase 1 Study of PBTZ169 | Biotech Hunter | Biotech Hunter